TXG
10x Genomics, Inc.
October 6, 2026 · intraday
- Rarity
- 2.46
- Peak move
- −18.32%
- Float cap
- $11.0B
10x Genomics, Inc. is a life sciences technology company that sells integrated research solutions, including instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. Its Chromium, Visium, and Xenium platforms help academic, translational, and biopharmaceutical researchers interrogate oncology, immunology, and neuroscience biology. The company markets to research laboratories and biopharmaceutical companies worldwide.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
8 events · 0 from SEC or newswire · 0 timed with the movepeer_disclosureXCENA signed an MOU with spatial omics company Portrai on Oct 6 to build CXL-based memory infrastructure for large-scale bio data, after pre-validating 10x Genomics' Atera spatial omics workload on its InfiniteMemory environment with roughly 35 million cells of data.
- Key event
analyst_ratingA FactSet survey of 15 analysts raised the median price target on 10x Genomics Class A to $65 from $60, an 8.33% increase, with a high of $110 and low of $40; of 18 analysts, 6 were bullish, 11 neutral and 1 bearish.
- Key event
institutional_flowARK's October 2 holdings disclosure showed Twist Bioscience (TWST) and 10x Genomics (TXG) as the two largest positions in the ARK Genomic Revolution ETF (ARKG) at a combined 20.27%, with TXG up 473% year-to-date and ARKG up 86%.
- Key event
institutional_flowARK Invest's Oct 2 holdings disclosure showed its ARK Genomic Revolution ETF (ARKG) held 2.51 million 10x Genomics shares worth $222.6 million, a 10.04% position and one of the fund's two largest holdings.
analyst_ratingLeerink raised its price target on 10x Genomics to $90 from $40 while keeping a Market Perform rating, citing the Atera launch's impact on Visium and Xenium but raising the target on peer-group comps.
product_launch10x Genomics began commercial shipments of its Atera spatial biology platform and introduced Sentira Spatial, a GPU-accelerated cloud analysis suite for Xenium and Atera users that shortens data processing from hours to minutes, with management saying orders already exceed the 2026 shipment target.
analyst_ratingPiper Sandler maintained a Neutral rating on 10x Genomics while raising its price target to $80 from $47.
analyst_ratingArgus Research initiated coverage of 10x Genomics with a Buy rating and a $110 price target, the highest on the Street, on the spatial biology opportunity and Atera ramp.